UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.712

Sortiert nach

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era

Annals of oncology, 2014-11, Vol.25 (11), p.2124-2133

2014

Link zum Volltext

Verfügbarkeit prüfen

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

Leukemia, 2012-06, Vol.26 (6), p.1356-1364

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Leukemia, 2011-02, Vol.25 (2), p.341-347

2011

Link zum Volltext

Verfügbarkeit prüfen

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2011-07, Vol.22 (7), p.1622-1627

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting Apoptosis Pathways in Cancer Therapy

CA: a cancer journal for clinicians, 2005-05, Vol.55 (3), p.178-194

2005

Link zum Volltext

Verfügbarkeit prüfen

Bowel perforation in intestinal lymphoma: incidence and clinical features

Annals of oncology, 2013-09, Vol.24 (9), p.2439-2443

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Annals of oncology, 2013-11, Vol.24 (11), p.2892-2897

2013

Link zum Volltext

Verfügbarkeit prüfen

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Leukemia, 2013-03, Vol.27 (3), p.680-685

2013

Link zum Volltext

Verfügbarkeit prüfen

The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling

Leukemia, 2010-09, Vol.24 (9), p.1641-1655

2010

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Annals of oncology, 2015-08, Vol.26 (8), p.1667-1677

2015

Link zum Volltext

Verfügbarkeit prüfen

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Leukemia, 2011-09, Vol.25 (9), p.1502-1509

2011

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib, a dual Raf kinase vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Oncogene, 2010-02, Vol.29 (8), p.1190-1202

2010

Link zum Volltext

Verfügbarkeit prüfen

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Leukemia, 2007-03, Vol.21 (3), p.529-534

2007

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Leukemia, 2013-01, Vol.27 (1), p.220-225

2013

Link zum Volltext

Verfügbarkeit prüfen

Anti‐CD20 monoclonal antibody‐dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages

Clinical and experimental immunology, 2016-01, Vol.183 (1), p.90-101

2016

Link zum Volltext

Verfügbarkeit prüfen

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma

Leukemia, 2018-02, Vol.32 (2), p.565-569

2018

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

Leukemia, 2011-12, Vol.25 (12), p.1877-1881

2011

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide as initial therapy for early-stage myeloma

Leukemia, 2003-04, Vol.17 (4), p.775-779

2003

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Annals of oncology, 2018-03, Vol.29 (3), p.707-714

2018

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma

Annals of oncology, 2016-01, Vol.27 (1), p.165-172

2016

Link zum Volltext

Verfügbarkeit prüfen

Incidence of bowel perforation in gastrointestinal lymphomas by location and histology

Annals of oncology, 2014-06, Vol.25 (6), p.1249-1250

2014

Link zum Volltext

Verfügbarkeit prüfen

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

Leukemia, 2017-04, Vol.31 (4), p.988-991

2017

Link zum Volltext

Verfügbarkeit prüfen

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations

Leukemia, 2005-08, Vol.19 (8), p.1466-1470

2005

Link zum Volltext

Verfügbarkeit prüfen

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

Leukemia, 2003-02, Vol.17 (2), p.427-436

2003

Link zum Volltext

Verfügbarkeit prüfen

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

Kidney international, 2008-06, Vol.73 (11), p.1282-1288

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.712

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.531)
Mit Volltextzugriff
(1.533)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.691)
Japanisch
(134)
Französisch
(12)
Deutsch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(714)
Humans
(641)
Life Sciences & Biomedicine
(634)
Female
(372)
Male
(367)
Middle Aged
(345)
Hematology
(337)
Aged
(325)
Biological And Medical Sciences
(303)
Medical Sciences
(293)
Adult
(292)
Oncology
(284)
Aged, 80 And Over
(190)
Hematologic And Hematopoietic Diseases
(158)
Prognosis
(148)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(147)
Treatment Outcome
(134)
Lymphoma
(107)
Disease-Free Survival
(93)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(84)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Targeting Apoptosis Pathways in Cancer Therapy

Bowel perforation in intestinal lymphoma: incidence and clinical features

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

Sorafenib, a dual Raf kinase vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Anti‐CD20 monoclonal antibody‐dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

Thalidomide as initial therapy for early-stage myeloma

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma

Incidence of bowel perforation in gastrointestinal lymphomas by location and histology

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

Suchergebnisse filtern